ASP isotopes

A LEADER IN ISOTOPE ENRICHMENT TECHNOLOGY FOR THE MEDICAL, GREEN ENERGY, AND INDUSTRIAL SECTORS

COMPANY OVERVIEW

ASP Isotopes is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company is initially focused on commercializing Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market, and Carbon-14, the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics.

INVESTMENT HIGHLIGHTS

Signed 25-year supply agreement valued at up to $27 million per annum

- Agreement for highly enriched Molybdenum-100 (Mo-100) with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy)

Signed multi-year supply agreement targeting $3.8 million revenue per annum

- Agreement for highly enriched Carbon-14 (C-14) with RC-14, a Canadian company
- Initial contract term is two years and can be extended to 10 years
- C-14 is the most frequently used radiolabel for drug discovery, drug metabolism, and pharmacokinetics

ASP technology is a low capital cost and environmentally friendly method of isotope production

- Isotope enrichment facilities using ASP technology can be constructed at a fraction of capital cost and time vs traditional facilities with small footprint plants and modular design enabling capacity expansion
- ASP technology harvests and enriches a natural mix of isotopes without need for nuclear reactor by-products; ASP plant produces zero waste (not radioactive nor any other waste in any form)

Geo-political uncertainty and plant phase-outs create significant opportunity

- Planned phase-out of 9 of 10 old research nuclear reactors over next decade creates large shortfall in the global supply for Mo-99 and other isotopes
- Russia and China previously key global suppliers of isotopes; recent geopolitical events have forced governments and other customers to reassess their reliance on these suppliers

Highly Experienced Leadership Team

- Paul Mann, Co-Founder, Chairman, CEO, CFO; 20+ years' experience on Wall Street investing in healthcare and chemicals companies, having worked at Soros Fund Management, Highbridge Capital Management and Morgan Stanley; began career as a research scientist at Proctor & Gamble
- Hendrik Strydom, PhD, Director, CTO; 30+ years' experience in isotope enrichment; co-developed isotope separation technology that is backbone of ASP Isotopes

(Nasdaq: ASPI)

ASP Isotopes, Inc.
HQ: Boca Raton, FL
Leadership Team
Chairman & CEO: Paul Mann
CTO: Hendrik Strydom, PhD
CFO: Robert Ainscow

Auditors: EisnerAmper LLP

MARKET DATA

Price[1]	$0.33
52-wk Range[1]	$0.28 - $3.75
Market Cap[1]	$12.4M
Shares Outstanding[1]	37.4M
Float[1]	19.0M
Avg. Volume (90-day)[1]	365,540
Cash (mrq)[2]	$5.1M
LT Debt (mrq)[2]	$0M

Fiscal Year: December 31

[1] as of June 1, 2023
[2] as of March 31, 2023

www.aspisotopes.com

VALUE PROPOSITION

ASP Isotopes successfully acquired two incomplete ASP plants in Pretoria, South Africa, and obtained the required licenses from the nuclear regulators, including the Non-proliferation Council of South Africa, to complete construction of the plants and produce commercial product. Cold commissioning of the first manufacturing plant, capable of enriching light isotopes, was completed in Q1 2023, and ASP Isotopes entered into a Memorandum of Understanding with a North American customer for the entire offtake of the Company's first light isotope plant. The Company intends to enter into "take or pay" style offtake agreements with customers, and by 2028, ASP Isotopes expects to be a leading supplier of non-nuclear enriched isotopes generating over $150 million in EBITDA per annum. In November 2022, the Company announced a 25-year supply agreement valued at up to $27 million per annum with BRICEM (Beijing Research Institute of Chemical Engineering Metallurgy) to supply highly enriched Molybdenum-100 (Mo-100). ASP Isotopes now expects to begin delivering commercial quantities of Mo-100 from Q3 2023 versus previous guidance of "before 2024" and continues to have discussions with BRICEM and other potential customers regarding the production of other isotopes.